Molecular Pathways: Next-Generation Immunotherapy—Inhibiting Programmed Death-Ligand 1 and Programmed Death-1
Daniel S. Chen, Bryan A. Irving, Frank Stephen Hodi · Clinical Cancer Research · 2012
The aim of T-cell-based immune therapy for cancer has been to generate durable clinical benefit for patients. Following a generation of therapies that largely showed minimal activity, substantial toxicity, and no biomarkers to identify which patients benefit from treatment, early studies are showing signs that programmed death-ligand 1 (PD-L1) and programmed death-1 (PD-1) inhibitors are highly active. Preclinical and early data from clinical studies suggest that targeting this pathway can induce durable clinical responses in patients in a variety of tumor types, including lung and colon cancer. Furthermore, correlations with tumor PD-L1 expression may enable selection of patients most likely to benefit from treatment. The emerging data not only offer the hope of better cancer therapy but also provide evidence that changes our understanding of how the host immune system interacts with human cancer.
Cited by 654 works. doi:10.1158/1078-0432.ccr-12-1362
Authors
References
- Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer
- The blockade of immune checkpoints in cancer immunotherapy
- Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer
- Tumor-associated B7-H1 promotes T-cell apoptosis: A potential mechanism of immune evasion
- Engagement of the Pd-1 Immunoinhibitory Receptor by a Novel B7 Family Member Leads to Negative Regulation of Lymphocyte Activation
- Phase I Study of Single-Agent Anti–Programmed Death-1 (MDX-1106) in Refractory Solid Tumors: Safety, Clinical Activity, Pharmacodynamics, and Immunologic Correlates
- PD-L2 is a second ligand for PD-1 and inhibits T cell activation
- Colocalization of Inflammatory Response with B7-H1 Expression in Human Melanocytic Lesions Supports an Adaptive Resistance Mechanism of Immune Escape
- Cancer immunoediting: from immunosurveillance to tumor escape
- Cancer immunotherapy comes of age